CL2014002086A1 - Anticuerpos cd47 y métodos de uso los mismos - Google Patents

Anticuerpos cd47 y métodos de uso los mismos

Info

Publication number: CL2014002086A1
Authority: CL; Chile
Prior art keywords: antibodies; methods
Prior art date: 2012-02-06

Application number

CL2014002086A

Other languages

English (en)

Inventor

Brendan Eckelman

John Timmer

Amir Razai

Quinn Deveraux

Kyle Jones

Peter L Nguy

Original Assignee

Inhibrx Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-02-06

Filing date

2014-08-06

Publication date

2015-02-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48947976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002086(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-08-06 Application filed by Inhibrx Llc filed Critical Inhibrx Llc

2015-02-27 Publication of CL2014002086A1 publication Critical patent/CL2014002086A1/es

Links

101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 title 1
102100032913 Leukocyte surface antigen CD47 Human genes 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Mycology (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CL2014002086A 2012-02-06 2014-08-06 Anticuerpos cd47 y métodos de uso los mismos CL2014002086A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261595216P	2012-02-06	2012-02-06
US201261659752P	2012-06-14	2012-06-14

Publications (1)

Publication Number	Publication Date
CL2014002086A1 true CL2014002086A1 (es)	2015-02-27

Family

ID=48947976

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002086A CL2014002086A1 (es)	2012-02-06	2014-08-06	Anticuerpos cd47 y métodos de uso los mismos

Country Status (35)

Country	Link
US (4)	US9045541B2 (es)
EP (2)	EP3578569A1 (es)
JP (1)	JP6273212B2 (es)
KR (2)	KR102100388B1 (es)
CN (2)	CN111533804A (es)
AU (1)	AU2013217114B2 (es)
BR (1)	BR112014019331A2 (es)
CA (1)	CA2863834A1 (es)
CL (1)	CL2014002086A1 (es)
CO (1)	CO7111273A2 (es)
CR (1)	CR20140406A (es)
CY (1)	CY1121911T1 (es)
DK (1)	DK2812443T3 (es)
EA (1)	EA034778B1 (es)
EC (1)	ECSP14016994A (es)
ES (1)	ES2743203T3 (es)
HR (1)	HRP20191500T1 (es)
HU (1)	HUE13746964T2 (es)
IL (1)	IL233934B (es)
LT (1)	LT2812443T (es)
ME (1)	ME03512B (es)
MX (1)	MX360772B (es)
MY (1)	MY169341A (es)
NZ (1)	NZ628314A (es)
PE (1)	PE20141908A1 (es)
PH (1)	PH12014501758B1 (es)
PL (1)	PL2812443T3 (es)
PT (1)	PT2812443T (es)
RS (1)	RS59159B1 (es)
SG (2)	SG11201404638SA (es)
SI (1)	SI2812443T1 (es)
SM (1)	SMT201900453T1 (es)
UA (1)	UA116772C2 (es)
WO (1)	WO2013119714A1 (es)
ZA (1)	ZA201405864B (es)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2995315T (pt)	2009-05-15	2024-03-14	Hospital For Sick Children	Composições e métodos para o tratamento de cancros hematológicos que visam a interação sirpa-cd47
PT3604339T (pt)	2011-01-14	2021-04-13	Univ California	Anticorpos terapêuticos contra a proteína ror-1 e métodos para utilização dos mesmos
US20140140989A1 (en) *	2012-02-06	2014-05-22	Inhibrx Llc	Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
US9045541B2 (en)	2012-02-06	2015-06-02	Inhibrx Llc	CD47 antibodies and methods of use thereof
RU2019118257A (ru)	2012-12-03	2019-06-24	Новиммун С.А.	Анти-cd47 антитела и способы их применения
KR20150093770A (ko)	2012-12-12	2015-08-18	베스쿨럭스 인코포레이티드	치료적 ｃｄ４７ 항체
US9221908B2 (en)	2012-12-12	2015-12-29	Vasculox, Inc.	Therapeutic CD47 antibodies
CA3145468A1 (en)	2012-12-17	2014-06-26	Trillium Therapeutics Inc.	Treatment of cd47+ disease cells with sirp alpha-fc fusions
JP2016507555A (ja) *	2013-02-06	2016-03-10	インヒブルクスエルピー	血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法
EP3792285A1 (en) *	2013-03-15	2021-03-17	The Board of Trustees of the Leland Stanford Junior University	Methods for achieving therapeutically effective doses of anti-cd47 agents
PL3828203T3 (pl) *	2013-12-17	2024-10-21	Mhs Care - Innovation Llc	Kompozycje i sposoby leczenia nagromadzenia tkanki tłuszczowej
US11066467B2 (en)	2013-12-17	2021-07-20	Mhs Care-Innovation Llc	Compositions and methods for treating ischemic heart disease
AU2015204766B2 (en) *	2014-01-08	2020-08-13	The Board Of Trustees Of The Leland Stanford Junior University	Targeted therapy for small cell lung cancer
CA2967379A1 (en)	2014-11-18	2016-05-26	Janssen Pharmaceutica Nv	Cd47 antibodies, methods, and uses
SG10202007176TA (en) *	2014-12-30	2020-08-28	Celgene Corp	Anti-cd47 antibodies and uses thereof
WO2016118754A1 (en) *	2015-01-21	2016-07-28	The Board Of Trustees Of The Leland Stanford Junior University	Macrophages eat cancer cells using their own calreticulin as a guide
MA41463A (fr) *	2015-02-03	2017-12-12	Anaptysbio Inc	Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
US20170151281A1 (en)	2015-02-19	2017-06-01	Batu Biologics, Inc.	Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
AU2016225993B2 (en) *	2015-03-04	2020-09-24	Yuhan Corporation	Antibody therapeutics that bind CD47
CN104804093A (zh) *	2015-05-27	2015-07-29	江苏春申堂药业有限公司	一种针对cd47的单域抗体
CN108348589B (zh)	2015-09-18	2022-09-23	安驰肿瘤公司	治疗性cd47抗体
CA2999277A1 (en)	2015-09-21	2017-03-30	Surface Oncology, Inc.	Anti-cd47 antibodies and methods of use
ES2796378T3 (es)	2016-01-11	2020-11-26	Forty Seven Inc	Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos
US11472878B2 (en)	2016-04-15	2022-10-18	The Board Of Trustees Of The Leland Stanford Junior University	Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
WO2017196793A1 (en) *	2016-05-09	2017-11-16	Celgene Corporation	Cd47 antibodies and methods of use thereof
CN106084052B (zh) *	2016-06-17	2019-12-27	长春金赛药业股份有限公司	抗cd47单克隆抗体及其应用
US12344669B2 (en)	2016-06-17	2025-07-01	Changchun Genescience Pharmaceutical Co., Ltd.	Anti-CD47 monoclonal antibody and use thereof
CN106117354B (zh) *	2016-06-24	2020-01-14	安徽未名细胞治疗有限公司	一种全人源抗CD47的全分子IgG抗体及其应用
KR20190035737A (ko) *	2016-07-06	2019-04-03	셀진 코포레이션	낮은 면역원성을 갖는 항체 및 이의 용도
WO2018014068A1 (en) *	2016-07-19	2018-01-25	Teva Pharmaceuticals Australia Pty Ltd	Attenuated type i ifn cd47 combination therapy
CA3030926A1 (en)	2016-07-19	2018-01-25	Teva Pharmaceuticals Australia Pty Ltd.	Anti-cd47 combination therapy
CN107955071B (zh) *	2016-10-18	2021-03-26	上海赛远生物科技有限公司	人源抗人cd47抗体及其编码基因与应用
MX2019004691A (es) *	2016-10-20	2019-12-09	I Mab Biopharma Us Ltd	Anticuerpos monoclonales cd47 novedosos y sus usos.
WO2018075960A1 (en)	2016-10-21	2018-04-26	Tioma Therapeutics, Inc.	Therapeutic cd47 antibodies
PL3532497T3 (pl)	2016-10-26	2024-11-04	The Board Of Trustees Of The Leland Stanford Junior University	Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji
US11779631B2 (en)	2016-11-03	2023-10-10	Pfizer Inc.	CD47 blockade therapy by HDAC inhibitors
CA3042581A1 (en)	2016-11-03	2018-05-11	Trillium Therapeutics Inc.	Enhancement of cd47 blockade therapy by proteasome inhibitors
WO2018095428A1 (zh) *	2016-11-28	2018-05-31	江苏恒瑞医药股份有限公司	Cd47抗体、其抗原结合片段及其医药用途
AU2018213718B2 (en) *	2017-01-26	2022-08-25	Zlip Holding Limited	CD47 antigen binding unit and uses thereof
CA3057139A1 (en) *	2017-03-22	2018-09-27	Arch Oncology, Inc.	Combination therapy for the treatment of solid and hematological cancers
TWI871272B (zh)	2017-04-11	2025-02-01	美商因荷布瑞克斯生物科學公司	具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
AU2018252193B2 (en)	2017-04-14	2024-12-12	Tallac Therapeutics, Inc.	Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
WO2018236904A1 (en)	2017-06-19	2018-12-27	Surface Oncology, Inc.	Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
CN109096395B (zh) *	2017-06-20	2022-06-24	华兰生物工程股份有限公司	阻断型cd47纳米抗体及其用途
EP3747437A1 (en)	2017-07-24	2020-12-09	Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis	Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction
CN111183155B (zh) *	2017-08-02	2024-02-20	凡恩世制药(北京)有限公司	抗cd47抗体及其用途
ES2911243T3 (es) *	2017-08-10	2022-05-18	Grifols Diagnostic Solutions Inc	Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano
CN111212852A (zh)	2017-08-18	2020-05-29	超人肆有限公司	结合剂
CN109422811A (zh) *	2017-08-29	2019-03-05	信达生物制药(苏州)有限公司	抗cd47抗体及其用途
EA039662B1 (ru)	2017-10-03	2022-02-24	Закрытое Акционерное Общество "Биокад"	Антитела, специфичные к cd47 и pd-l1
CN111417653A (zh)	2017-11-01	2020-07-14	蜂鸟生物科技控股私人有限公司	Cd47抗原结合分子
KR20220028157A (ko) *	2017-11-10	2022-03-08	아이-맵 바이오파마 유에스 리미티드	Cd47 항체 및 사이토카인을 포함하는 융합 단백질
AU2018375375A1 (en)	2017-12-01	2020-05-28	Seagen Inc.	CD47 antibodies and uses thereof for treating cancer
EP3743108A4 (en) *	2018-01-24	2022-01-26	Nanjing Legend Biotech Co., Ltd.	ANTI-CD47 ANTIBODIES THAT DO NOT CAUSE SIGNIFICANT RBC AGGLUTINATION
CN110144009B (zh) *	2018-02-14	2020-01-21	上海洛启生物医药技术有限公司	Cd47单域抗体及其用途
GB201804860D0 (en)	2018-03-27	2018-05-09	Ultrahuman Two Ltd	CD47 Binding agents
CN110305212A (zh)	2018-03-27	2019-10-08	信达生物制药(苏州)有限公司	抗cd47抗体及其用途
SG11202009804RA (en)	2018-04-11	2020-11-27	Inhibrx Inc	Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
WO2019200357A1 (en)	2018-04-12	2019-10-17	Surface Oncology, Inc.	Biomarker for cd47 targeting therapeutics and uses therefor
CN110526972A (zh) *	2018-05-25	2019-12-03	江苏恒瑞医药股份有限公司	一种抗cd47抗体在制备治疗淋巴瘤的药物中的用途
CN110577597B (zh)	2018-06-11	2021-10-22	康诺亚生物医药科技（成都）有限公司	一种阻断CD47和SIRPα相互作用的抗体
WO2019241732A1 (en) *	2018-06-15	2019-12-19	Accurus Biosciences, Inc.	Blocking antibodies against cd47 and methods of use thereof
CN110615841B (zh) *	2018-06-20	2022-01-04	瑞阳(苏州)生物科技有限公司	抗人cd47单克隆抗体及其应用
EP3813884B1 (en) *	2018-06-29	2024-09-18	North Carolina State University	In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
EP3817769A4 (en) *	2018-07-05	2022-03-30	Trican Biotechnology Co., Ltd	Human anti-cd47 antibodies and uses thereof
EP3845561A4 (en) *	2018-08-31	2022-07-06	Nanjing Sanhome Pharmaceutical Co., Ltd.	ANTI-CD47 ANTIBODIES AND ITS USE
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
SG11202104301SA (en) *	2018-10-31	2021-05-28	I Mab Biopharma Us Ltd	Novel cd47 antibodies and methods of using same
WO2020097193A1 (en)	2018-11-06	2020-05-14	The Regents Of The University Of California	Chimeric antigen receptors for phagocytosis
CN111253488A (zh) *	2018-12-03	2020-06-09	上海开拓者生物医药有限公司	Cd47抗体及其制备方法和应用
TW202104260A (zh)	2019-04-05	2021-02-01	美商西建公司	腫瘤選擇性結合ｃｄ４７之抗體之工程
US11026973B2 (en)	2019-04-30	2021-06-08	Myeloid Therapeutics, Inc.	Engineered phagocytic receptor compositions and methods of use thereof
CN110066336B (zh) *	2019-05-12	2021-11-09	杭州科兴生物科技有限公司	抗cd47单克隆抗体、片段及其医药用途
JP7561775B2 (ja)	2019-06-07	2024-10-04	エーエルエックスオンコロジーインコーポレイテッド	血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬
PH12021553197A1 (en) *	2019-06-19	2022-11-07	Lepu Biopharma Co Ltd	Anti-cd47 antibodies and uses thereof
JP7454645B2 (ja)	2019-07-16	2024-03-22	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖワクチン並びにその作製方法及び使用方法
CN110256565B (zh) *	2019-08-02	2021-03-23	天津大学	抗cd47纳米抗体突变体及其应用
EP4025686A4 (en)	2019-09-03	2023-09-13	Myeloid Therapeutics, Inc.	Methods and compositions for genomic integration
CN114786776A (zh)	2019-09-18	2022-07-22	拉姆卡普生物阿尔法股份公司	针对ceacam5和cd3的双特异性抗体
CA3156160A1 (en) *	2019-09-27	2021-04-01	Beijing Starmab Biomed Technology Ltd.	Monospecific and multi-specific antibodies
EP4045083B1 (en)	2019-10-18	2024-01-10	Forty Seven, Inc.	Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
US12410250B2 (en)	2019-10-25	2025-09-09	WuXi Biologics Ireland Limited	Anti-CD47 antibodies and uses thereof
JP2022552748A (ja)	2019-10-31	2022-12-19	フォーティセブン，インコーポレイテッド	抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
US10980836B1 (en)	2019-12-11	2021-04-20	Myeloid Therapeutics, Inc.	Therapeutic cell compositions and methods of manufacturing and use thereof
GB201918230D0 (en)	2019-12-11	2020-01-22	Prec Therapeutics Ltd	Antibodies and their uses
PT4081305T (pt)	2019-12-24	2024-12-04	Gilead Sciences Inc	Compostos moduladores da diacilglicerol quinase
CA3169451A1 (en)	2020-02-14	2021-08-19	Jounce Therapeutics, Inc.	Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2021170082A1 (zh)	2020-02-28	2021-09-02	南京圣和药业股份有限公司	抗cd47/抗pd-l1抗体及其应用
WO2021174091A1 (en)	2020-02-28	2021-09-02	Tallac Therapeutics, Inc.	Transglutaminase-mediated conjugation
US12091681B2 (en)	2020-03-27	2024-09-17	Mendus B.V.	Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CA3182607A1 (en)	2020-06-30	2022-01-06	Erik Hans MANTING	Use of leukemia-derived cells in ovarian cancer vaccines
JP2023537331A (ja) *	2020-07-31	2023-08-31	バイオ－テラソリュ－ションズ，エルティーディー．	Ｃｄ４７抗体及びその応用
EP4225793A1 (en)	2020-10-07	2023-08-16	Celgene Corporation	Bispecific antibody treatment of lymphoid malignant neoplasm conditions
EP4237451A1 (en)	2020-11-02	2023-09-06	Hummingbird Bioscience Pte. Ltd.	Bcma/taci antigen-binding molecules
IL302639A (en)	2020-11-04	2023-07-01	Myeloid Therapeutics Inc	Engineered chimeric fusion protein compositions and methods of use thereof
WO2022120286A1 (en)	2020-12-06	2022-06-09	ALX Oncology Inc.	Multimers for reducing the interference of drugs that bind cd47 in serological assays
KR102757518B1 (ko) *	2020-12-07	2025-01-21	(주)이노베이션바이오	Cd47에 특이적인 항체 및 이의 용도
WO2022130016A1 (en)	2020-12-18	2022-06-23	Instil Bio (Uk) Limited	Tumor infiltrating lymphocytes and anti-cd47 therapeutics
CN116761823A (zh) *	2021-01-05	2023-09-15	北京生命科学研究所	靶向gpc3和cd47的双特异性抗体
WO2022190058A1 (en)	2021-03-12	2022-09-15	Dcprime B.V.	Methods of vaccination and use of cd47 blockade
IL305950A (en)	2021-03-17	2023-11-01	Myeloid Therapeutics Inc	Engineered chimeric fusion protein compositions and methods of using them
TW202302145A (zh)	2021-04-14	2023-01-16	美商基利科學股份有限公司	ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
BR112023023642A2 (pt)	2021-05-11	2024-01-30	Myeloid Therapeutics Inc	Métodos e composições para integração genômica
EP4359413A1 (en)	2021-06-23	2024-05-01	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
JP7654118B2 (ja)	2021-06-23	2025-03-31	ギリアードサイエンシーズ，インコーポレイテッド	ジアシルグリセロールキナーゼ調節化合物
JP7651018B2 (ja)	2021-06-23	2025-03-25	ギリアードサイエンシーズ，インコーポレイテッド	ジアシルグリセロールキナーゼ調節化合物
WO2022271677A1 (en)	2021-06-23	2022-12-29	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
JP2024527335A (ja)	2021-06-30	2024-07-24	イノベイションバイオカンパニーリミテッド	Ｃｄ４７に特異的なヒト化抗体およびそれを含むｃｄ４７関連疾患の予防または治療用医薬組成物
TWI857377B (zh)	2021-10-28	2024-10-01	美商基利科學股份有限公司	嗒-3(2h)-酮衍生物
EP4422756A1 (en)	2021-10-29	2024-09-04	Gilead Sciences, Inc.	Cd73 compounds
JP2024546851A (ja)	2021-12-22	2024-12-26	ギリアードサイエンシーズ，インコーポレイテッド	Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
EP4452415A1 (en)	2021-12-22	2024-10-30	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh)	2022-01-28	2023-10-16	美商基利科學股份有限公司	Ｐａｒｐ７抑制劑
WO2023154578A1 (en)	2022-02-14	2023-08-17	Sana Biotechnology, Inc.	Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
PE20242225A1 (es)	2022-03-17	2024-11-19	Gilead Sciences Inc	Degradadores de dedos de zinc de la familia ikaros y usos de estos
WO2023183313A1 (en)	2022-03-22	2023-09-28	Sana Biotechnology, Inc.	Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
US20230355796A1 (en)	2022-03-24	2023-11-09	Gilead Sciences, Inc.	Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh)	2022-04-05	2025-03-11	美商基利科學股份有限公司	用於治療結腸直腸癌之組合療法
IL316058A (en)	2022-04-21	2024-11-01	Gilead Sciences Inc	Compounds modulate KRAS G12D
EP4547657A1 (en)	2022-07-01	2025-05-07	Gilead Sciences, Inc.	Cd73 compounds
AU2023307100A1 (en)	2022-07-12	2025-01-02	Gilead Sciences, Inc.	Hiv immunogenic polypeptides and vaccines and uses thereof
US20240091351A1 (en)	2022-09-21	2024-03-21	Gilead Sciences, Inc.	FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
EP4630121A1 (en)	2022-12-09	2025-10-15	Pfizer Inc.	Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy
TW202440151A (zh)	2022-12-09	2024-10-16	美商輝瑞大藥廠	Ｃｄ４７阻斷劑及抗ｃｄ２０／抗ｃｄ３雙特異性抗體組合療法
CN118221812A (zh) *	2022-12-14	2024-06-21	上海迈石生物技术有限公司	一种靶向cd47的单克隆抗体及其应用
KR20250122479A (ko)	2022-12-22	2025-08-13	길리애드 사이언시즈, 인코포레이티드	Prmt5 억제제 및 이의 용도
WO2024177978A1 (en) *	2023-02-24	2024-08-29	The Regents Of The University Of California	Lilrb3 engager cells
WO2024215754A1 (en)	2023-04-11	2024-10-17	Gilead Sciences, Inc.	Kras modulating compounds
WO2024220917A1 (en)	2023-04-21	2024-10-24	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
US20250042922A1 (en)	2023-06-30	2025-02-06	Gilead Sciences, Inc.	Kras modulating compounds
US20250066328A1 (en)	2023-07-26	2025-02-27	Gilead Sciences, Inc.	Parp7 inhibitors
US20250100998A1 (en)	2023-07-26	2025-03-27	Gilead Sciences, Inc.	Parp7 inhibitors
US20250101042A1 (en)	2023-09-08	2025-03-27	Gilead Sciences, Inc.	Kras g12d modulating compounds
WO2025054530A1 (en)	2023-09-08	2025-03-13	Gilead Sciences, Inc.	Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
CN117004700A (zh) *	2023-10-07	2023-11-07	北京爱博生生物技术有限公司	单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒
US20250154172A1 (en)	2023-11-03	2025-05-15	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
US20250230168A1 (en)	2023-12-22	2025-07-17	Gilead Sciences, Inc.	Azaspiro wrn inhibitors

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
FR2413974A1 (fr)	1978-01-06	1979-08-03	David Bernard	Sechoir pour feuilles imprimees par serigraphie
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4681581A (en)	1983-12-05	1987-07-21	Coates Fredrica V	Adjustable size diaper and folding method therefor
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5776093A (en)	1985-07-05	1998-07-07	Immunomedics, Inc.	Method for imaging and treating organs and tissues
US5101827A (en)	1985-07-05	1992-04-07	Immunomedics, Inc.	Lymphographic and organ imaging method and kit
US4735210A (en)	1985-07-05	1988-04-05	Immunomedics, Inc.	Lymphographic and organ imaging method and kit
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5030719A (en)	1986-08-28	1991-07-09	Teijin Limited	Cytotoxic antibody conjugates and a process for preparation thereof
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5648471A (en)	1987-12-03	1997-07-15	Centocor, Inc.	One vial method for labeling antibodies with Technetium-99m
US5057604A (en)	1988-08-03	1991-10-15	Washington University	Novel monoclonal antibodies
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ATE144793T1 (de)	1989-06-29	1996-11-15	Medarex Inc	Bispezifische reagenzien für die aids-therapie
CA2065299C (en)	1989-08-09	2001-07-24	Buck A. Rhodes	Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
KR100272077B1 (ko)	1990-08-29	2000-11-15	젠팜인터내셔날,인코포레이티드	이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
ATE352612T1 (de)	1990-08-29	2007-02-15	Pharming Intellectual Pty Bv	Homologe rekombination in säugetier-zellen
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5194594A (en)	1990-09-07	1993-03-16	Techniclone, Inc.	Modified antibodies
JPH06507398A (ja)	1991-05-14	1994-08-25	リプリジェン　コーポレーション	Ｈｉｖ感染治療のための異種複合抗体
WO1992022670A1 (en)	1991-06-12	1992-12-23	Genpharm International, Inc.	Early detection of transgenic embryos
AU2235992A (en)	1991-06-14	1993-01-12	Genpharm International, Inc.	Transgenic immunodeficient non-human animals
WO1993004169A1 (en)	1991-08-20	1993-03-04	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
ES2227512T3 (es)	1991-12-02	2005-04-01	Medical Research Council	Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
AU3328493A (en)	1991-12-17	1993-07-19	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5777085A (en)	1991-12-20	1998-07-07	Protein Design Labs, Inc.	Humanized antibodies reactive with GPIIB/IIIA
EP0592677B1 (en)	1992-02-18	2001-11-07	Otsuka Kagaku Kabushiki Kaisha	Beta-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF
US5233409A (en)	1992-02-25	1993-08-03	Schwab Karl W	Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
AU4541093A (en)	1992-06-18	1994-01-24	Genpharm International, Inc.	Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
AU675661B2 (en)	1992-07-24	1997-02-13	Abgenix, Inc.	Generation of xenogeneic antibodies
EP0752248B1 (en)	1992-11-13	2000-09-27	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JPH08509612A (ja)	1993-04-26	1996-10-15	ジェンファームインターナショナルインコーポレイテッド	異種抗体を産生することができるトランスジェニック非ヒト動物
AU6794594A (en)	1993-04-30	1994-11-21	Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh	Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (tgf-beta )
EP0703979B1 (en)	1993-06-04	2000-09-13	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Method for treating kaposi's sarcoma with antisense oligonucleotides
US5625825A (en)	1993-10-21	1997-04-29	Lsi Logic Corporation	Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
WO1995022618A1 (en)	1994-02-22	1995-08-24	Dana-Farber Cancer Institute	Nucleic acid delivery system, method of synthesis and uses thereof
US5643763A (en)	1994-11-04	1997-07-01	Genpharm International, Inc.	Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5703057A (en)	1995-04-07	1997-12-30	Board Of Regents The University Of Texas System	Expression library immunization
WO1996034096A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
ATE352613T1 (de)	1995-08-29	2007-02-15	Kirin Brewery	Chimäres tier und methode zu dessen herstellung
US6025130A (en)	1996-04-04	2000-02-15	Mercator Genetics, Inc.	Hereditary hemochromatosis gene
KR100643058B1 (ko)	1996-12-03	2006-11-13	아브게닉스, 인크.	복수의 Ｖн 및 Ｖк 영역을 함유하는 인간 면역글로불린 유전자좌를 갖는 트랜스제닉 포유동물 및 이로부터 생성된 항체
ATE395362T1 (de) *	1997-09-11	2008-05-15	Chugai Pharmaceutical Co Ltd	Monoklonale antikörper zur apoptosis-induzierung
AU2940900A (en)	1999-03-10	2000-09-28	Chugai Seiyaku Kabushiki Kaisha	Single-stranded fv inducing apoptosis
US6833268B1 (en)	1999-06-10	2004-12-21	Abgenix, Inc.	Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU2002315052A1 (en) *	2001-05-15	2002-11-25	Emory University	Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47
KR100454414B1 (ko)	2001-06-25	2004-10-26	주식회사 진생사이언스	산소를 이용한 개량 홍삼의 제조 방법
WO2004014292A2 (en)	2002-05-10	2004-02-19	Purdue Research Foundation	EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
JP2005528115A (ja)	2002-05-31	2005-09-22	ザボードオブトラスティーズオブザリーランドスタンフォードジュニアユニバーシティ	幹細胞および癌幹細胞を同定および単離する方法
US20100215640A1 (en)	2003-04-24	2010-08-26	The University Of North Carolina At Chapel Hill	Method for inhibiting cellular activation by insulin-like growth factor-1
US20040213792A1 (en)	2003-04-24	2004-10-28	Clemmons David R.	Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en)	2003-04-24	2013-12-24	The University Of North Carolina At Chapel Hill	Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
CA2545166A1 (en) *	2003-11-11	2005-05-19	Chugai Seiyaku Kabushiki Kaisha	Humanized anti-cd47 antibody
JP4970948B2 (ja)	2003-12-05	2012-07-11	ボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティ	癌幹細胞の同定、単離、および除去の方法
US8568725B2 (en)	2003-12-25	2013-10-29	Kyowa Hakko Kirin Co., Ltd.	Method of treating transplant rejection with an anti-CD40 antibody
AU2005214988A1 (en) *	2004-02-17	2005-09-01	Absalus, Inc.	Super-humanized antibodies against respiratory syncytial virus
US8187595B2 (en)	2004-05-07	2012-05-29	The University Of North Carolina At Chapel Hill	Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
DK1755660T3 (da)	2004-05-07	2010-07-19	Univ North Carolina	Fremgangsmåde til forbedring eller hæmning af insulin-lignende vækstfaktor-I
US7728880B2 (en)	2004-06-25	2010-06-01	Qualcomm Incorporated	Automatic white balance method and apparatus
WO2007027714A2 (en)	2005-08-31	2007-03-08	Schering Corporation	Engineered anti-il-23 antibodies
US7514229B2 (en)	2005-09-29	2009-04-07	The Board Of Trustees Of The Leland Stanford Junior University	Methods for diagnosing and evaluating treatment of blood disorders
US20090191202A1 (en)	2005-09-29	2009-07-30	Jamieson Catriona Helen M	Methods for manipulating phagocytosis mediated by CD47
EP2027151A2 (en) *	2006-05-15	2009-02-25	Viral Logic Systems Technology Corp.	Cd47 related compositions and methods for treating immunological diseases and disorders
MX2010000970A (es) *	2007-07-31	2010-03-09	Regeneron Pharma	Anticuerpos humanos contra cd20 humano y metodo para utilizarlos.
CA2706419A1 (en)	2007-11-30	2009-06-04	Glaxo Group Limited	Antigen-binding constructs binding il-13
DK2242512T3 (en)	2008-01-15	2016-06-06	Univ Leland Stanford Junior	Method for manipulating phagocytosis mediated by CD47
EP4470556A3 (en)	2008-01-15	2025-04-23	The Board of Trustees of the Leland Stanford Junior University	Markers of acute myeloid leukemia stem cells
KR100962704B1 (ko)	2008-07-02	2010-06-11	유상규	일측 단말의 제어로 타 단말의 주변장치를 이용하는 단말장치 및 그 인터페이스 방법
WO2010017598A1 (en)	2008-08-14	2010-02-18	Arana Therapeutics Limited	Anti-il-12/il-23 antibodies
NZ592432A (en) *	2008-11-03	2013-01-25	Alethia Biotherapeutics Inc	Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
EP2477648B1 (en)	2009-09-15	2022-07-20	The Board of Trustees of the Leland Stanford Junior University	Synergistic anti-cd47 therapy for hematologic cancers
US9151760B2 (en)	2009-09-29	2015-10-06	The Board Of Trustees Of The Leland Stanford Junior University	Isolation and use of melanoma cancer stem cells
US20120283124A1 (en)	2009-11-10	2012-11-08	Park Christopher Y	Cell Surface Marker Expression in Hematopoietic Stem Cells and Progenitors for the Diagnosis, Prognosis, and Treatment of Myelodysplastic Syndromes
WO2011143624A2 (en)	2010-05-14	2011-11-17	The Board Of Trustees Of The Leland Stanford Junior University	Humanized and chimeric monoclonal antibodies to cd47
US20130281304A1 (en)	2010-08-13	2013-10-24	Andrew P. Feinberg	Comprehensive Methylome Map of Myeloid and Lymphoid Commitment from Hematopoietic Proenitors
US20140271683A1 (en)	2010-12-21	2014-09-18	The Board Of Trustees Of The Leland Stanford Junior University	Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor
JP6460796B2 (ja)	2012-01-17	2019-01-30	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	高親和性ｓｉｒｐ−アルファ試薬
US9045541B2 (en)	2012-02-06	2015-06-02	Inhibrx Llc	CD47 antibodies and methods of use thereof
US20140140989A1 (en) *	2012-02-06	2014-05-22	Inhibrx Llc	Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
MX2015002465A (es)	2012-08-31	2015-11-06	Univ North Carolina	Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
JP2016507555A (ja)	2013-02-06	2016-03-10	インヒブルクスエルピー	血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法
US9111624B2 (en)	2013-03-22	2015-08-18	Katsuyuki Fujita	Semiconductor memory device

2013
- 2013-02-06 US US13/761,087 patent/US9045541B2/en active Active
- 2013-02-06 HR HRP20191500 patent/HRP20191500T1/hr unknown
- 2013-02-06 NZ NZ628314A patent/NZ628314A/en unknown
- 2013-02-06 RS RSP20191071 patent/RS59159B1/sr unknown
- 2013-02-06 CA CA2863834A patent/CA2863834A1/en active Pending
- 2013-02-06 SG SG11201404638SA patent/SG11201404638SA/en unknown
- 2013-02-06 EP EP19173042.3A patent/EP3578569A1/en active Pending
- 2013-02-06 DK DK13746964.9T patent/DK2812443T3/da active
- 2013-02-06 MX MX2014009427A patent/MX360772B/es active IP Right Grant
- 2013-02-06 PE PE2014001225A patent/PE20141908A1/es not_active Application Discontinuation
- 2013-02-06 EA EA201400875A patent/EA034778B1/ru not_active IP Right Cessation
- 2013-02-06 ES ES13746964T patent/ES2743203T3/es active Active
- 2013-02-06 SG SG10201700160RA patent/SG10201700160RA/en unknown
- 2013-02-06 WO PCT/US2013/024995 patent/WO2013119714A1/en active Application Filing
- 2013-02-06 SM SM20190453T patent/SMT201900453T1/it unknown
- 2013-02-06 KR KR1020147025286A patent/KR102100388B1/ko active Active
- 2013-02-06 ME MEP-2019-232A patent/ME03512B/me unknown
- 2013-02-06 CN CN202010418862.1A patent/CN111533804A/zh active Pending
- 2013-02-06 HU HUE13746964A patent/HUE13746964T2/hu unknown
- 2013-02-06 JP JP2014556634A patent/JP6273212B2/ja active Active
- 2013-02-06 CN CN201380017900.0A patent/CN104271757B/zh active Active
- 2013-02-06 AU AU2013217114A patent/AU2013217114B2/en active Active
- 2013-02-06 KR KR1020207009892A patent/KR102338833B1/ko active Active
- 2013-02-06 PT PT13746964T patent/PT2812443T/pt unknown
- 2013-02-06 PL PL13746964T patent/PL2812443T3/pl unknown
- 2013-02-06 LT LTEP13746964.9T patent/LT2812443T/lt unknown
- 2013-02-06 EP EP13746964.9A patent/EP2812443B1/en active Active
- 2013-02-06 BR BR112014019331A patent/BR112014019331A2/pt not_active Application Discontinuation
- 2013-02-06 SI SI201331564T patent/SI2812443T1/sl unknown
- 2013-02-06 MY MYPI2014002294A patent/MY169341A/en unknown
- 2013-06-02 UA UAA201409709A patent/UA116772C2/uk unknown
2014
- 2014-08-04 IL IL233934A patent/IL233934B/en unknown
- 2014-08-05 PH PH12014501758A patent/PH12014501758B1/en unknown
- 2014-08-06 CO CO14171778A patent/CO7111273A2/es unknown
- 2014-08-06 CL CL2014002086A patent/CL2014002086A1/es unknown
- 2014-08-11 ZA ZA2014/05864A patent/ZA201405864B/en unknown
- 2014-09-01 CR CR20140406A patent/CR20140406A/es unknown
- 2014-09-02 EC ECIEPI201416994A patent/ECSP14016994A/es unknown
2015
- 2015-04-29 US US14/700,105 patent/US9663575B2/en active Active
- 2015-08-31 US US14/841,619 patent/US20160251435A1/en not_active Abandoned
2019
- 2019-08-19 CY CY20191100884T patent/CY1121911T1/el unknown
2021
- 2021-02-08 US US17/170,854 patent/US20210317205A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CR20140406A (es)	2014-12-10
HUE13746964T2 (hu)	2020-01-28
HRP20191500T1 (hr)	2019-11-29
CA2863834A1 (en)	2013-08-15
KR20200040897A (ko)	2020-04-20
UA116772C2 (uk)	2018-05-10
KR102338833B1 (ko)	2021-12-13
CY1121911T1 (el)	2020-10-14
JP2015508072A (ja)	2015-03-16
LT2812443T (lt)	2019-09-10
US9045541B2 (en)	2015-06-02
KR102100388B1 (ko)	2020-04-13
DK2812443T3 (da)	2019-08-26
KR20150008049A (ko)	2015-01-21
PL2812443T3 (pl)	2020-01-31
US20130224188A1 (en)	2013-08-29
PH12014501758B1 (en)	2019-03-06
PE20141908A1 (es)	2014-12-21
SG10201700160RA (en)	2017-03-30
BR112014019331A8 (pt)	2018-01-16
ES2743203T3 (es)	2020-02-18
US20160251435A1 (en)	2016-09-01
EP2812443A1 (en)	2014-12-17
CN104271757A (zh)	2015-01-07
IL233934B (en)	2022-04-01
ZA201405864B (en)	2015-11-25
IL233934A0 (en)	2014-09-30
RS59159B1 (sr)	2019-10-31
EP3578569A1 (en)	2019-12-11
CN111533804A (zh)	2020-08-14
AU2013217114B2 (en)	2017-03-30
MX360772B (es)	2018-11-15
US9663575B2 (en)	2017-05-30
EA201400875A1 (ru)	2015-01-30
EP2812443A4 (en)	2015-11-04
MY169341A (en)	2019-03-21
NZ628314A (en)	2017-01-27
US20210317205A1 (en)	2021-10-14
PH12014501758A1 (en)	2014-11-10
BR112014019331A2 (pt)	2022-07-12
JP6273212B2 (ja)	2018-01-31
WO2013119714A1 (en)	2013-08-15
MX2014009427A (es)	2015-05-11
SI2812443T1 (sl)	2019-10-30
ECSP14016994A (es)	2015-09-30
SG11201404638SA (en)	2014-09-26
CN104271757B (zh)	2020-06-09
PT2812443T (pt)	2019-09-05
SMT201900453T1 (it)	2019-11-13
US20150238604A1 (en)	2015-08-27
HK1205195A1 (en)	2015-12-11
CO7111273A2 (es)	2014-11-10
EA034778B1 (ru)	2020-03-19
ME03512B (me)	2020-04-20
AU2013217114A1 (en)	2014-09-18
EP2812443B1 (en)	2019-05-29

Publication	Publication Date	Title
CL2014002086A1 (es)	2015-02-27	Anticuerpos cd47 y métodos de uso los mismos
CO7000747A2 (es)	2014-07-21	Anticuerpos anti-lrp5 y métodos de uso
CL2016001556A1 (es)	2017-02-03	Anticuerpos anti-cd3 y métodos de uso
CO6821892A2 (es)	2013-12-31	Anticuerpos anti-angptl3 y usos de los mismos
CO7020870A2 (es)	2014-08-11	Anticuerpos anti-htra1 y métodos de uso
BR112014028366A2 (pt)	2017-06-27	anticorpos anti-ly6e e imunoconjugados e métodos de uso
CO6940383A2 (es)	2014-05-09	Anticuerpos anti-erbb3 y usos de los mismos
CL2015001266A1 (es)	2015-08-28	Anticuerpos de antihemaglutinina y métodos de uso.
CL2016001102A1 (es)	2017-02-10	Anticuerpos anti-claudina novedosos y métodos de uso.
CL2016000251A1 (es)	2017-07-14	Anticuerpos anti-activina y usos de los mismos
CL2016003052A1 (es)	2017-08-04	Anticuerpos anti-ox40 y métodos de uso de los mismos (divisional de sol. n° 2526-15).
BR112014012590A2 (pt)	2017-06-20	anticorpos anti-cd98 e métodos de uso dos mesmos
CL2015001321A1 (es)	2015-07-17	Anticuerpos anti-ceacam5 y usos de éstos
BR112014002716A2 (pt)	2017-06-13	anticorpos anti-poliubiquitina e métodos de uso
BR112014018136A2 (pt)	2018-09-11	anticorpos ou uso e método para determinar
CL2015000582A1 (es)	2015-11-06	Anticuerpos anti-mcam y métodos asociados de uso
CO6980627A2 (es)	2014-06-27	Anticuerpos anti-pfh-tau y sus usos
CR20150380A (es)	2015-08-21	Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
CO6950471A2 (es)	2014-05-20	Pirimidinas anilladas sustituidas y uso de las mismas
CO7020859A2 (es)	2014-08-11	Anticuerpos anti-cd134 (ox40) y usos de los mismos
CO6801741A2 (es)	2013-11-29	Derivados c4-monometil triterpenoides y sus métodos de uso
BR112014012137A2 (pt)	2017-05-30	anticorpos anti-fgfr2 e suas utilizações
BR112014010175A2 (pt)	2017-04-25	unidades de filtro, componentes e recursos destas e métodos de uso e construção
CO6940376A2 (es)	2014-05-09	Anticuerpos anti-psgl-1 y usos de los mismos
BR112013014119A2 (pt)	2016-09-27	novos moduladores e métodos de uso